Loading
companiesCompany
Diffusion Pharmaceuticals
Diffusion developed trans sodium crocetinate, a small molecule meant to carry more oxygen into tumours so radiotherapy works better; its phase 3 trial in glioblastoma was cut short and the company merged into another biotech in 2023.
Also called: Diffusion Pharmaceuticals IncDiffusion Pharmaceuticals LLC
Overview
Diffusion Pharmaceuticals, founded in 2001 in Charlottesville, Virginia, developed trans sodium crocetinate (TSC), a carotenoid derivative that increases oxygen diffusion into hypoxic tissue, as a radiosensitiser. Its phase 3 INTACT trial in newly diagnosed glioblastoma was terminated early, and the company merged with EIP Pharma in 2023. Its trials remain on ClinicalTrials.gov under Diffusion as lead sponsor.
Headquarters
Charlottesville, VA, US
Type
Stage
Acquired
Website
Founded
2001
Similar pages
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- TreatmentNimorazole
Shares Tumour hypoxia: imaging and modification, Radiosensitisers.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed